Merck & Co. Inc. (MRK) — closed signal from April 15, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on July 14, 2026.
Predicted vs. what happened
MRK price · publication thesis → realized outcomesplit-adjusted
$114.35 – $118.29Entry zone — fair-value band
$118.12Published — price the day we called it
$126.66Target — the price the thesis aimed for
$130.29Peak — highest point inside the window, not a realized return
$120.78Window close — end-of-window price, context only
What happened
Target reached
Reached its target in 72 days.
Peak price
$130.29
peak on June 30, 2026 — not a realized returnPeak gain
+10.3%
peak, from the publication priceWindow close
$120.78
end-of-window price, context onlyDays to target
72
Window
April 15, 2026 – July 14, 2026
The thesis — published April 15, 2026
Predicted growth
+8%
over the measurement windowTarget price
$126.66
the price the thesis aimed forEntry zone
$114.35 – $118.29
the fair-value band we waited forPrice at publication
$118.12
published April 15, 2026Confidence
70%
how strongly the data lined upTimeframe
Short-term (0–3 months)
Merck looks like a safer healthcare pick for the next few months. A regulatory priority review for a partnered lung cancer drug is a real news event that can lift sentiment. Shares are trading near a lower price area rather than high levels, and earnings are steady rather than fast-growing. It could benefit if investors shift toward more stable names.
Primary drivers
- Regulatory priority review provides a clear drug-related news event
- Steady earnings make the company more resilient in downturns
- Stock trading near a lower price area offers a cleaner entry
- Healthcare status helps if investors favor stable sectors
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Lyra
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.